Biotechnology and the Federal Circuit, Second Edition, with 2017 Cumulative Supplement

This treatise for patent prosecutors, litigators, and in-house counsel discusses major court decisions in chemical, biotechnology, and pharmaceutical cases within the context of the current law. It contains an incomparably thorough subject-matter index, a table of cases, a table of statutes and regulations cited, and text and footnote references updated to include extensive cross-references to major Federal Circuit cases.

Meet The Authors

Kenneth J. Burchfiel
Main Volume Author
Howard W. Levine
Supplement Author


Main Volume Information

Biotechnology and the Federal Circuit, Second Edition is the only reference work that provides an in-depth consideration of the entire body of Federal Circuit precedent in the rapidly developing area of biotechnology. This treatise integrates the court’s decisions in chemical, biotechnology and pharmaceutical cases with an analysis of the current law. Unique in its detailed discussion of precedent and critical analysis of jurisprudence, patent prosecutors, litigators and in-house counsel alike can count on this treatise for the guidance to navigate through the labyrinth of Federal Circuit biotechnology patent law.

The Second Edition offers full analysis and incisive, expert commentary on recent en banc Federal Circuit and Supreme Court decisions which have rewritten the law applied to biotechnology inventions and altered the basic legal principles governing patentability and infringement. It includes extensive revisions and updates to the original volume and supplements, and encompasses the most recent Federal Circuit precedent, including comprehensive analysis and discussion of:

  • KSR v. Teleflex, the Federal Circuit’s biotechnology and pharmaceutical decision applying the Supreme Court’s analysis of obviousness and motivation to combine prior art teachings, including the revived “obvious to try” standard
  • Abbott v. Sandoz, the Federal Circuit’s fundamental product-by-process decision and its implications for patentability and infringement of biotechnology process patents
  • In re Bilski, and its implications for patentability of biotechnology inventions involving quantitative analysis and processes involving the application of algorithms, including the Federal Circuit’s decision in Prometheus v. Mayo
  • Written description and the evolution of the requirement leading to the court’s en banc decision in Ariad v. Eli Lilly (including its application in In re Wallach), Capon v. Eshhar, University of Rochester v. Searle, Invitrogen v. Clontech, Carnegie Mellon. v. Hoffman-La Roche, and In re Alonso, as well as the revised 2008 USPTO Guidelines and training materials
  • Utility and the court’s “practical utility” standard for patentability, including its decisions in In re Fischer, Rasmusson v. SKB, and In re ’318 Patent Litigation
  • The Hatch-Waxman Act and Supreme Court and Federal Circuit precedent concerning the safe harbor for medical and pharmaceutical research, including Merck v. Integra, and a Federal Circuit precedent governing generic pharmaceutical infringement litigation under §271(e)(2)
  • Patent term and term extension, including USPTO delays under §154 and FDA regulatory delays under §156, and their interrelationship under the 20-year patent term
  • Infringement and the various standards of claim construction approved in Phillips v. AWH, as well as the application in subsequent biotechnology and pharmaceutical infringement decisions, including Amgen v. Hoechst

Biotechnology and the Federal Circuit, Second Edition also contains incomparable research aids, including the most thorough subject-matter index available; a completely revised table of cases, and a table of statutes and regulations cited; and text and footnote references updated to include extensive cross-references to recent Federal Circuit cases.

Supplement Information   

The 2017 Cumulative Supplement provides full analysis of recent Supreme Court and Federal Circuit decisions, including: 

  • How the Federal Circuit has continued to interpret the Supreme Court’s decision in Mayo v. Prometheus and, in particular, how the various judges of the court addressed the permissible bounds of patent eligible subject matter in Ariosa Diagnostics, Inc. v. Sequenom, Inc.
  • The evolving standard of review for claim construction
  • The continuing split regarding how differing panels of the Federal Circuit resolve the key issue of obviousness under Section 103 for biotechnology and pharmaceutical inventions
  • The changed law of indefiniteness and its application by the court
  • The treatment of the PTAB decisions in post-grant proceedings by the Federal Circuit
  • And more


Bloomberg BNA authors and editors are practicing professionals with insider perspectives and real-life experience. Learn more about this book’s authors and editors.
Kenneth J. Burchfiel is a partner in Sughrue Mion, PLLC, Washington, D.C.
Howard W. Levine is a partner with Finnegan, Henderson, Farabow, Garrett & Dunner, LLP in Washington, D.C.


View full tables of contents and read the book’s preface or introduction.